Dataset Information

Proteomic analysis of fecal Mucin-2 from humans and mice

ABSTRACT: Proteomic analysis of extracted and partially purified fecal mucin-2 from human and mouse stool

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Epithelial Cell, Colon

SUBMITTER: Kirk Bergstrom

LAB HEAD: Kirk Bergstrom

PROVIDER: PXD048242 | Pride | 2024-06-22

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 7

Publications

Fecal-adherent mucus is a non-invasive source of primary human MUC2 for structural and functional characterization in health and disease.

Fancy Noah N Nitin Kniffen Darrek D Melvin Mackenzie M Kazemian Negin N Sadeghi Javad J Letef Clara A CA D'Aloisio Leah L Copp Amanda G AG Inaba Rain R Hans Geetkamal G Jafaripour Simin S Haskey Natasha N Raman Maitreyi M Daneshgar Pirandis P Chadee Kris K Ghosh Sanjoy S Gibson Deanna L DL Pakpour Sepideh S Zandberg Wesley W Bergstrom Kirk S B KSB

The Journal of biological chemistry 20240124 3

The O-glycoprotein Mucin-2 (MUC2) forms the protective colon mucus layer. While animal models have demonstrated the importance of Muc2, few studies have explored human MUC2 in similar depth. Recent studies have revealed that secreted MUC2 is bound to human feces. We hypothesized human fecal MUC2 (HF-MUC2) was accessible for purification and downstream structural and functional characterization. We tested this via histologic and quantitative imaging on human fecal sections; extraction from feces ...[more]

PMID: 38272223

Similar Datasets

Project description:We describe a simple method, Digital Restriction Enzyme Analysis of Methylation (DREAM), based on sequential DNA digestion with a pair of methylation-blocked and methylation-tolerant neoschizomeric restriction enzymes SmaI/XmaI followed by end repair and ultra-deep sequencing. DREAM provides information on 160,000 unique CpG sites of which 39,000 are in CpG islands, and 33,000 are at transcription start sites (-1 kb to +1 kb) of 13,139 RefSeq genes. We compared DNA methylation values in white blood cells from 4 healthy individuals and found them to be remarkably uniform. Interindividual differences >30% were observed only at 227 of 28,331 (0.8%) of autosomal CCCGGG sites covered by 100+ sequencing reads. Similarly, differences at only 59 sites were observed between the cord and adult blood. Conserved methylation patterns in healthy blood cells contrasted with extensive changes affecting 18-40% of CpG sites in leukemia. The method is cost effective, quantitative (r2=0.93 when compared to bisulfite pyrosequencing), reproducible (r2=0.997), and can detect differences >25% with false positive rate <0.001. Accurate analysis of changes in DNA methylation will be useful in quantifying epigenetic effects of environment and nutrition, correlating developmental epigenetic variation with phenotypes, understanding epigenetics of cancer and chronic diseases, measuring the effects of drugs on DNA methylation or deriving new biological insights into mammalian genomes. Digital restriction enzyme analysis of methylation (DREAM) was performed to determine the DNA methylation profiles of healthy white blood cells from cord blood and adult blood, acute myeloid leukemia bone marrow, and two leukemia cell lines (HEL and K562). In this approach, genomic DNA is sequentially cut at CCCGGG sites with the methylation-sensitive enzyme SmaI (blunt ends) and its methylation-tolerant neoschizomer XmaI (5'CCGG overhangs), creating different end sequences that represent methylation status of the CCCGGG sites. These end sequences are analyzed by next-generation sequencing, and thereafter the methylation status at individual CCCGGG sites across the genome can be determined.

			Action	DRS
	20211125_KB-01.raw	Raw
	20211125_KB-02.raw	Raw
	20211125_KB-03.raw	Raw
	Fig2_Proteomics.xlsx	Xlsx
	REC-2270_Bergstrom_Report_copy.doc	Other